OPKO Health, Inc. Announces Appointment of Anthony Japour as New Director
January 08, 2020 at 09:20 pm
Share
On January 6, 2020, the Board of Directors of OPKO Health, Inc. appointed Anthony Japour, M.D. as a new director effective as of January 6, 2020 to serve until the Company’s 2020 Annual Meeting of Stockholders and until his successor shall be duly elected or appointed or his earlier death or resignation.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
OPKO HEALTH, INC. 
